Drug Survival and Long-term Outcome of Tofacitinib in Patients with Alopecia Areata: A Retrospective Study
Acta Dermato-Venereologica · 13.11.2023 · 103 · adv13475
DOI: 10.2340/actadv.v103.13475 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Acta Dermato-Venereologica, online erschienen am 13.11.2023. Verfasst von Jundong Huang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, PR China. Hauptthemen laut MEDLINE: Alopecia Areata. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Several non-randomized clinical trials and retrospective studies have demonstrated encouraging efficacy and well-tolerated safety of tofacitinib in the treatment of alopecia areata. However, there are scarce data on a large cohort of patients with alopecia areata in long-term real-world practice. This single-centre, retrospective, observational cohort study included 126 patients with alopecia areata treated with tofacitinib between February 2021 and December 2022. The aims of this study are to evaluate drug survival, effectiveness and safety of tofacitinib for treatment of alopecia areata, and to identify potential factors influencing long-term outcomes. Median duration of treatment was 23.00 (interquartile range (IQR) 15.00, 47.25) weeks. Median all-cause survival time of 126 patients treated with tofacitinib was 44 weeks (95% confidence interval (95% CI) 36.3, 51.7), and the all-cause drug retention rate at 12 weeks, 24 weeks and 48 weeks were 90.0%, 66.4% and 42.3%, respectively. The most common reason for discontinuation was complete remission/satisfaction. A total of 80 patients treated with tofacitinib for over 6 months were included in the efficacy analysis, the overall complete response rate at 24 weeks was 33.8% (27/80). No life-threatening serious adverse events occurred. Sex is an independent risk factor in predicting patient outcomes. This real-world study confirmed the high effectiveness and acceptable safety profile of tofacitinib in alopecia areata, with a satisfactory drug survival rate, and provides supporting data for the clinical application of tofacitinib in Chinese patients with alopecia areata.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, PR China.
- Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, PR China; Hunan key laboratory of aging biology, Xiangya Hospital, Central South University, Changsha, China; National Clinical Res…
- DDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, PR China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan,…
- Department of Dermatology, The Second Xiangya Hospital, Central South University, Hunan Key Laboratory of Medical Epigenomics, Changsha, Hunan, PR China. scarlett0512@csu.edu.cn.
Zitieren
APA
Huang, J., Deng, S., Li, J., Tang, Y., Liu, F., Liu, Y., Rao, S., & Shi, W. (2023). Drug Survival and Long-term Outcome of Tofacitinib in Patients with Alopecia Areata: A Retrospective Study. Acta Dermato-Venereologica, 103, adv13475. https://doi.org/10.2340/actadv.v103.13475
Vancouver
Huang J, Deng S, Li J, Tang Y, Liu F, Liu Y, et al. Drug Survival and Long-term Outcome of Tofacitinib in Patients with Alopecia Areata: A Retrospective Study. Acta Dermato-Venereologica. 2023;103:adv13475. doi:10.2340/actadv.v103.13475
BibTeX
@article{Huang2023,
author = {Huang, Jundong and Deng, Sihan and Li, Ji and Tang, Yan and Liu, Fangfen and Liu, Yu and Rao, Shijia and Shi, Wei},
title = {Drug Survival and Long-term Outcome of Tofacitinib in Patients with Alopecia Areata: A Retrospective Study},
journal = {Acta Dermato-Venereologica},
year = {2023},
volume = {103},
pages = {adv13475},
doi = {10.2340/actadv.v103.13475}
}
EUVIMED